

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
00101/0487	Novartis Pharmaceuticals UK Limited	Estraderm MX 50	Oestradiol Hemihydrate 1.540 mg	at risk of developing fractures. Epidemiological studies suggest a number of risk factors may contribute to postmenopausal osteoporosis, including: Early menopause (either natural or surgically induced) Family history of osteoporosis Recent prolonged corticosteroid therapy A small, thin frame Excessive cigarette consumption If several risk factors are present, consideration should be given to hormone replacement therapy. Bone mineral density measurements may help to confirm the presence of low bone mass. For maximum prophylactic benefit treatment should commence as soon as possible after the menopause. Oestrogen therapy must not be used in patients with an intact uterus unless an appropriate dose of progestogen is administered for 12 days per month. Prescription Only Medicine (See PL/00101/0486)	12th September 1997
00101/0488	Novartis Pharmaceuticals UK Ltd	Estraderm MX 100	Oestradiol Hemihydrate 3.090 mg	(See PL 00101/0486) Prescription Only Medicine	12th September 1997
00101/0489	Novartis Pharmaceuticals UK Ltd	Estraderm TTS 25	17-B-Oestradiol USP 2.0 mg	Oestrogen replacement therapy for patients with disorders due to natural or surgically induced menopause eg vasomotor symptoms (hot flushes and nocturnal sweating), urogenital conditions such as atrophic vaginitis/vulvitis and/or atrophic urethritis and trigonitis. Prescription Only Medicine	12th September 1997
00101/0490	Novartis Pharmaceuticals UK Ltd	Estraderm TTS 50	17-B-Oestradiol USP 4.0 mg	Oestrogen replacement therapy for patients with disorders due to natural or surgically induced menopause eg vasomotor symptoms (hot flushes and nocturnal sweating), urogenital conditions such as atrophic vaginitis/vulvitis and/or atrophic urethritis and trigonitis. Prevention of postmenopausal osteoporosis in women considered at risk of developing fractures. Epidemiological studies suggest a number of risk factors may contribute to postmenopausal osteoporosis, including: early menopause (either natural or surgically induced); family history of osteoporosis; recent prolonged corticosteroid therapy; a small, thin frame; excessive cigarette consumption. If several risk factors are present consideration should be given to hormone replacement therapy. Bone mineral density measurements may help to confirm the presence of low bone mass. For maximum prophylactic benefit treatment should commence as soon as possible after the menopause. Prescription Only Medicine (See PL00101/0489)	12th September 1997
00101/0491	Novartis Pharmaceuticals UK Ltd	Estraderm TTS 100	17-B-Oestradiol USP 8.0 mg	(See PL00101/0489) Prescription Only Medicine	12th September 1997
00101/0492	Novartis Pharmaceuticals UK Ltd	Estrapak 50	Transdermal Therapeutic System (Patch) 17-Beta-Oestradiol USP 4.0 mg	(See PL00101/0485) Prescription Only Medicine	12th September 1997
00101/0493	Novartis Pharmaceuticals UK Ltd	Femara	Tablet Norethisterone Acetate BP 1.0 mg Letrozole 2.500 mg	Treatment of advanced breast cancer in postmenopausal women in whom tamoxifen or other anti-oestrogen has failed. Prescription Only Medicine	21st September 1997
00101/0494	Novartis Pharmaceuticals UK Ltd	Foradil	Eformoterol Fumarate 12.000 mcg	The treatment of reversible airways obstruction (including nocturnal asthma and prevention of exercise induced bronchospasm) in patients requiring long-term regular bronchodilator therapy. Such patients should normally also be receiving regular and adequate doses of inhaled anti-inflammatory agents (eg corticosteroids and/or sodium cromoglycate) or oral corticosteroids.	15th September 1997
00101/0496	Novartis Pharmaceuticals UK Limited	Hygroton Tablets 100 mg	Chlorthalidone EP 100.0 mg	For the treatment of mild to moderate hypertension. Also for the treatment of diabetes insipidus and oedema associated with cardiac failure, renal or hepatic disease. Prescription Only Medicine	21st September 1997